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Aneurysm Diameter The absence of a disease-specific questionnaire for
use in patients with lower limb ischaemia led us toSir,
develop the “Vascuqol” at Kings’ College Hospital.In their recent article,1 Aarts et al. make the following
We followed methodology set out by Guyatt2 for thisreference to our previous work:2 “As described by
task and following item selection and reduction pro-Lederle et al., the variability for measuring aneurysm
duced a questionnaire that was tested for validity,diameters is decreased by using electronic calipers and
reliability and responsiveness alongside the SF-36.a magnifying glass”. This statement is included in
Each item in the Vascuqol is answered using a sevensupport of their conclusion that “measurements on
point Likert scale. We demonstrated that the King’shard copy are not accurate enough for sizing in TPEG”.
Vascuqol was more reliable and more responsive toIn fact, our study used mechanical calipers and a
change in patients with lower limb ischaemia com-magnifying glass on hard copy CT scans mailed from
pared to the SF-36.3 However, the King’s Vascuqol (inmultiple centres, with measurements made against the
common with any disease specific instrument) shouldscale provided on the film. The intraobserver vari-
be used in addition to generic quality of life measures.ability of our method appears to be comparable to the
The Walking Impairment Questionnaire (WIQ) de-electronic calipers method tested by Aarts et al., and
veloped by Hiatt and Regenstiener was mentioned asbetter than the “ruler and hard copy” method they
an example of a disease specific instrument. It shouldstudied. Retrospective measurement studies using
be made clear that the WIQ is a functional scale andarchived CT scans are much more readily conducted
does not measure quality of life. The Vascuqol alsothan studies requiring digital CT data available on a
avoids the criticism rightly made of the WIQ, in thatworkstation, and our data suggest that archival studies
the patients’ estimate of walking distance was not used;can be done without loss of accuracy.
rather we asked for the patients’ own perception of
whether they could walk further (or less) than before.F. A. Lederle
True validation of the Vascuqol will come with use.Minneapolis, U.S.A.
At present it is being administered alongside the SF-
36 in the Bypass versus Angioplasty in the SevereReferences
Ischaemia of the Leg (BASIL) study, a multicentre UK
1 Aarts NJM, Schurink GWH, Schultze Kool LJ et al. Abdominal trial co-ordinated by Professor A. Bradbury.
aortic aneurysm measurements for endovascular repair: intra- It is available for international use, and has so farand interobserver variability of CT measurements. Eur J Vasc
Endovasc Surg 1999; 18: 475–480. been formally translated into Dutch, French, German,
2 Lederle FA, Wilson SE, Johnson GR et al. for the Abdominal Italian, Swedish, Canadian French, as well as U.S. and
Aortic Aneurysm Detection and Management Veterans Ad-
Canadian English.4ministration Cooperative Study Group. Variability in measure-
ment of abdominal aortic aneurysms. J Vasc Surg 1995; 21: 945–952. The final paragraph states that a patient assessed
measure of health outcome that quantifies the impact
of intermittent claudication on aspects of health and
Health Outcomes well being is needed. Such an instrument already
exists. The King’s Vascuqol was developed with thisSir,
aim in mind and is available for use.We read with interest the editorial regarding patient-
assessed health outcomes in peripheral arterial dis- M. B. F. Morgan,
ease.1 We agree that quality of life measurement in S. C. A. Fraser
addition to traditional measures of clinical ex- London, U.K.,
amination, blood pressure indices, graft patency, limb and A. Bradbury
salvage and patient survival should be accepted as Birmingham, U.K.
best practice.
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2 Morgan MBF, Crayford T, Murrin B, Fraser SCA. DevelopingReferences
the King’s Vascuqol: a disease-specific quality of life measure for
patients with lower limb ischaemia. Br J Surg 1999; 86 (Suppl. 1):
1 Golledge J, Garratt A, Greenhalgh RM, Davies AH. Patient- 46.
assessed health outcomes in peripheral arterial disease. Eur J Vasc
Endovasc Surg 2000; 19: 109–110.
2 Guyatt GH, Bombardier C, Tugwell PX. Measuring disease Carotid Endarterectomy
specific quality of life in clinical trials. Can Med Assoc J 1986; 134:
889–895.
Sir,3 Morgan MBF, Crayford T, Murrin B, Fraser SCA. Developing
the King’s Vascuqol: a disease-specific quality of life measure for We read with great interest the article by Peiper et al.1
patients with lower limb ischaemia. Br J Surg 1999; 86 (Suppl. 1): concerning the early and late outcomes of carotid46.
eversion endarterectomy (CEE) compared with tra-4 Conway K, Uzun V, Girod, Morgan M, Koch P. Linguistic
validation of the vascular quality of life questionnaire (Vascuqol) ditional carotid endarterectomy with patch closure
in 8 languages. Presented to the ISPOR fifth annual international (CEAP). In this retrospective study the authors con-meeting, May 21–24, 2000. Washington.
cluded that the safety and durability of the two surgical
techniques were comparable. We have recently pub-
Author’s Reply lished three papers2–4 on the same subject, so we would
like to offer some comments on the issues raised by
We thank Messrs Morgan, Fraser and Bradbury for Peiper et al.1 In the first prospective study regarding
their interesting comments in response to the editorial 336 primary carotid endarterectomies (CEAs) per-
on “Patient-assessed health outcomes in peripheral formed in 310 patients, randomly attributed to two
arterial disease”.1 groups (169 CEEs and 167 CEAPs),3 we found that
We agree that the assessment of quality of life should CEE is generally superior to the gold standard CEAP
be integral in the design of future trials to determine in reducing perioperative stroke risk rate (0% vs. 2.9%;
the optimal therapy for intermittent claudication. Until p=0.03) as well as late occlusive events (0% vs. 3.7%;
recently, most studies for lower limb peripheral vas- p=0.01), though the outcome of the CEAP technique
cular disease have focussed on measures of patency in our hands correlated well with the results of the
as outcome measures. We are aware that the “Va- principal multicentre trials. Our second prospective
scuqol”2 has been developed for the assessment of
study4 confirmed our findings regarding clinical out-quality of life in peripheral vascular disease, but we feel
come and the incidence of restenosis in 86 patientsthat its use in patients with intermittent claudication is
undergoing bilateral CEA, in whom CEAP was per-limited by a fundamental methodology flaw in its
formed on one side and CEE on the other. Patients weredevelopment. Patients with intermittent claudication
randomly selected for sequential surgical treatmentdo not experience the problems of rest pain or tissue
involving either patching/eversion or eversion/patch-loss, as evident in patients with critical limb ischaemia.
ing. The overall perioperative mortality was 0%, and,Unfortunately, four out of 21 items in the “Vascuqol”
though the difference in the incidence of perioperativerelate to problems that are more relevant to patients
ipsilateral ischaemic stroke was not significant (3.5%with critical limb ischaemia. Item 7 “Pain in the foot
vs. 0%), the greater rate of combined transient isch-(or leg) after going to bed at night”, item 8 “pins and
aemic events and strokes with CEAP approached sig-needles and numbness”, item 13 “pain in the foot (or
nificance (7% vs. 1.2%; p=0.06). In addition, CEAPleg) when at rest” and item 17 “ulcers in the leg (or
had a significantly higher incidence of restenoses (4.7%foot)” are simply not applicable for the claudicant and
vs. 0%; p=0.02) and of combined late occlusive eventstherefore invalidate the “Vascuqol” when scored for
and restenoses (13% vs. 1.2%; p=0.004). The betterpatients with intermittent claudication. Therefore we
results appear to be related: (1) to the significantlybelieve that the “Vascuqol” is not a true condition-
lower carotid cross-clamping time required for CEE,specific quality of life measure for intermittent clau-
which avoids the need to selectively use an in-dication, which is still required and we therefore can-
traluminal shunt; and (2) to the improvement in severalnot recommend it as a valid outcome measure in
technical details, i.e. the routine correction of the re-studies for intermittent claudication.
sidual distal internal carotid artery elongation andP. F. S. Chong and A. H. Davies
preservation of the original carotid configuration, espe-London, U.K.
cially with regard to the inclination and amplitude of
the ostium of the internal carotid artery.References
On the basis of these findings, we are enthusiastic
1 Golledge J, Garratt AM, Greenhalgh RM, Davies AH. Patient- about the CEE – hence our interest in obtaining moreassessed health outcomes in peripheral arterial disease. Eur J Vasc
Endovasc Surg 2000; 19: 109–110. information concerning the results reported with CEE
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